BRIEF published on 08/04/2025 at 14:05, 1 year 2 months ago Medincell Announces its 2025 General Meeting Governance General Meeting Resolutions Remuneration Medincell
PRESS RELEASE published on 08/04/2025 at 14:00, 1 year 2 months ago Informations privilégiées / Autres communiqués Medincell publie la convocation pour son assemblée générale annuelle mixte 2025, incluant des résolutions sur les comptes, l'approbation des dirigeants et des délégations au Conseil d'administration Assemblée Générale Convocation Resolutions Pharmaceutique Medincell
BRIEF published on 07/30/2025 at 14:34, 1 year 3 months ago Medincell's Rising Revenue and Upcoming Submissions Schizophrenia Treatment Teva Partnership Medincell Revenue UZEDY Sales Olanzapine Submission
BRIEF published on 07/30/2025 at 14:34, 1 year 3 months ago Chiffre d'affaires croissant de Medincell et prochaines soumissions Traitement De La Schizophrénie Chiffre D'affaires De Medincell Ventes UZEDY Soumission D'olanzapine Partenariat Teva
PRESS RELEASE published on 07/30/2025 at 14:32, 1 year 3 months ago INFORMATIONS PRIVILÉGIÉES / AUTRES COMMUNIQUÉS Medincell accélère avec des prévisions de ventes 2025 relevées pour UZEDY® et confirmation de la demande de mise sur le marché américain pour l'Olanzapine LAI Schizophrénie Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 07/30/2025 at 14:29, 1 year 3 months ago INSIDE INFORMATION / OTHER NEWS RELEASES Medincell's partner Teva Pharmaceuticals raises 2025 revenue outlook for UZEDY® to $190–$200M and confirms Olanzapine LAI on track for submission in 2025 Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI Submission
BRIEF published on 07/30/2025 at 13:47, 1 year 3 months ago Medincell's UZEDY® and Olanzapine LAI Forecast Promising Financial Outcomes Schizophrenia Treatment Teva Pharmaceuticals Medincell Revenue Forecast UZEDY® Performance Olanzapine LAI Development
BRIEF published on 07/30/2025 at 13:47, 1 year 3 months ago Les prévisions de résultats financiers prometteurs pour les médicaments UZEDY® et Olanzapine LAI de Medincell Traitement De La Schizophrénie Teva Pharmaceuticals Prévisions De Revenus De Medincell Performances UZEDY® Développement De L'olanzapine LAI
PRESS RELEASE published on 07/30/2025 at 13:42, 1 year 3 months ago Inside Information / Other news releases Medincell's partner Teva increases 2025 revenue outlook for UZEDY® to $190–$200M, plans olanzapine LAI submission. Company's innovative treatments aim to improve medicine accessibility Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 07/30/2025 at 13:42, 1 year 3 months ago Informations privilégiées / Autres communiqués UZEDY® relève ses prévisions de ventes 2025 à 190–200 M$. Demande de mise sur le marché américain confirmée pour l'Olanzapine LAI en 2025. Medincell annonce les informations communiquées par Teva Pharmaceuticals Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY Ventes 2025
Published on 10/30/2026 at 23:35, 6 hours 1 minute ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 6 hours 6 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 8 hours 49 minutes ago CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 10 hours 36 minutes ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 14 hours 6 minutes ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/30/2026 at 22:49, 6 hours 47 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 10 hours 58 minutes ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 6 hours 36 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 6 hours 36 minutes ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
